{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:57:26Z","timestamp":1778903846101,"version":"3.51.4"},"reference-count":99,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.cgh.2013.06.006","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T04:03:09Z","timestamp":1372392189000},"page":"738-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hepatitis B and C in African Americans: Current Status and\u00a0Continued\u00a0Challenges"],"prefix":"10.1016","volume":"12","author":[{"given":"Kimberly A.","family":"Forde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orapin","family":"Tanapanpanit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2013.06.006_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-154-5-201103010-00006","article-title":"Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey","volume":"154","author":"Ioannou","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib2","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cgh.2013.06.006_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2893.2010.01401.x","article-title":"Is chronic hepatitis B being undertreated in the United States?","volume":"18","author":"Cohen","year":"2011","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cgh.2013.06.006_bib5","unstructured":"Centers for Disease Control and Prevention. Hepatitis B information for health professionals, 2012. Available at: http:\/\/www.cdc.gov\/hepatitis\/HBV\/HBVfaq.htm. Accessed November 17,\u00a02012."},{"key":"10.1016\/j.cgh.2013.06.006_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2105\/AJPH.89.1.14","article-title":"Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994","volume":"89","author":"McQuillan","year":"1999","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cgh.2013.06.006_bib7","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.2105\/AJPH.94.11.1952","article-title":"Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994","volume":"94","author":"McQuillan","year":"2004","journal-title":"Am J Public Health"},{"key":"10.1016\/j.cgh.2013.06.006_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cld.2010.05.007","article-title":"Natural history of chronic hepatitis B","volume":"14","author":"McMahon","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2013.06.006_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El-Serag","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2013.06.006_bib10","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1053\/j.gastro.2004.09.013","article-title":"Hepatocellular carcinoma: recent trends in the United States","volume":"127","author":"El-Serag","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cgh.2005.12.022","article-title":"Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000","volume":"4","author":"Yu","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jmv.20311","article-title":"Increased hepatocarcinogenic potential of hepatitis B virus genotype A in Bantu-speaking sub-saharan Africans","volume":"75","author":"Kew","year":"2005","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cgh.2013.06.006_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4254\/wjh.v2.i2.65","article-title":"Hepatocellular carcinoma in African Blacks: recent progress in etiology and pathogenesis","volume":"2","author":"Kew","year":"2010","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0016-5085(88)90434-9","article-title":"Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks","volume":"94","author":"Kew","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib16","first-page":"306","article-title":"Some characteristics of Mozambican Shangaans with primary hepatocellular cancer","volume":"51","author":"Kew","year":"1977","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.cgh.2013.06.006_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1478-3231.2010.02418.x","article-title":"Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in The Gambia","volume":"31","author":"Umoh","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2013.06.006_bib18","first-page":"552","article-title":"Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma","volume":"51","author":"Chen","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0016-5085(03)00895-3","article-title":"Hepatitis B virus genotypes in the United States: results of a nationwide study","volume":"125","author":"Chu","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0168-8278(00)80135-X","article-title":"Hepatitis B genotypes and the response to interferon therapy","volume":"33","author":"Kao","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib22","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib23","first-page":"1425","article-title":"HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C","volume":"36","author":"Wai","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib24","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1440-1746.2006.04304.x","article-title":"Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms","volume":"21","author":"Cheong","year":"2006","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1478-3231.2005.01241.x","article-title":"Interleukin-10 promoter polymorphisms are associated with the mode and sequel of HBeAg seroconversion in patients with chronic hepatitis B virus infection","volume":"26","author":"Peng","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2013.06.006_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1744-313X.2008.00770.x","article-title":"Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome","volume":"35","author":"Truelove","year":"2008","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.cgh.2013.06.006_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.gene.6364188","article-title":"Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance","volume":"6","author":"Oleksyk","year":"2005","journal-title":"Genes Immun"},{"key":"10.1016\/j.cgh.2013.06.006_bib28","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/gast.1997.v113.pm9352870","article-title":"Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa","volume":"113","author":"Lau","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib30","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States","volume":"341","author":"Dienstag","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B","volume":"36","author":"Perrillo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of serologic response after lamivudine treatment of chronic hepatitis B","volume":"37","author":"Dienstag","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1542-3565(04)00017-5","article-title":"Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B","volume":"2","author":"Kuo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2005.06.055","article-title":"A\u00a0dose-ranging study of\u00a0the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients","volume":"129","author":"Chang","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib38","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib39","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A\u00a0comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib40","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib42","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.22658","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir","volume":"49","author":"Leung","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib45","first-page":"384","article-title":"Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital","volume":"99","author":"Widjaja","year":"2007","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.cgh.2013.06.006_bib46","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/lt.20174","article-title":"Disparity in use of orthotopic liver transplantation among blacks and whites","volume":"10","author":"Reid","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2013.06.006_bib47","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2008.720","article-title":"Disparities in liver transplantation before and after introduction of the MELD score","volume":"300","author":"Moylan","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2013.06.006_bib48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/lt.20217","article-title":"Outcome of liver transplantation for hepatitis B in the United States","volume":"10","author":"Kim","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2013.06.006_bib49","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/lt.21759","article-title":"Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B","volume":"15","author":"Bzowej","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2013.06.006_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-132-2-200001180-00003","article-title":"45-year follow-up of hepatitis C virus infection in healthy young adults","volume":"132","author":"Seeff","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/01.mcg.0000225689.60335.44","article-title":"Hepatitis C in African Americans","volume":"41","author":"Pyrsopoulos","year":"2007","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2013.06.006_bib52","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib54","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib55","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib56","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1572-0241.2002.05555.x","article-title":"Hepatitis C infection in African Americans: its natural history and histological progression","volume":"97","author":"Wiley","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2013.06.006_bib57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.510300319","article-title":"Racial differences in responses to therapy with interferon in chronic hepatitis C: Consensus Interferon Study Group","volume":"30","author":"Reddy","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib58","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10620-011-1908-3","article-title":"Histological versus clinical cirrhosis in chronic hepatitis C: does race\/ethnicity really matter?","volume":"57","author":"Kohla","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2013.06.006_bib59","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1542-3565(04)00162-4","article-title":"Racial differences in liver inflammation and fibrosis related to chronic hepatitis C","volume":"2","author":"Crosse","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib60","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.cgh.2008.08.006","article-title":"Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C","volume":"6","author":"Terrault","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib61","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib62","first-page":"118","article-title":"Cancers with increasing incidence trends in the United States: 1999 through 2008","volume":"62","author":"Simard","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2013.06.006_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2036.2005.02602.x","article-title":"Review article: chronic hepatitis C\u2014natural history and cofactors","volume":"22","author":"Alberti","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2013.06.006_bib64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000024975","article-title":"Molecular evolution of hepatitis viruses","volume":"42","author":"Mizokami","year":"1999","journal-title":"Intervirology"},{"key":"10.1016\/j.cgh.2013.06.006_bib65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cld.2005.05.005","article-title":"Chronic hepatitis C in African Americans","volume":"9","author":"Pyrsopoulos","year":"2005","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2013.06.006_bib66","first-page":"1","article-title":"NIH consensus statement on management of hepatitis C: 2002","volume":"19","year":"2002","journal-title":"NIH Consens State"},{"key":"10.1016\/j.cgh.2013.06.006_bib67","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.20212","article-title":"Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1","volume":"39","author":"Jeffers","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib68","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib69","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib70","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.1128\/JVI.00487-07","article-title":"Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy","volume":"81","author":"Donlin","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cgh.2013.06.006_bib71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib72","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cgh.2013.06.006_bib73","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cgh.2013.06.006_bib74","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.cgh.2013.06.006_bib75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib76","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","article-title":"Replicated association between an IL28B gene variant and a sustained response to\u00a0pegylated interferon and ribavirin","volume":"138","author":"McCarthy","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib77","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is\u00a0associated with chronic hepatitis C and treatment failure: a\u00a0genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib79","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2013.06.006_bib80","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib81","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","article-title":"A\u00a0comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis: Multicenter Study Group","volume":"332","author":"Poynard","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib82","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1023\/A:1021750818611","article-title":"Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C","volume":"48","author":"Theodore","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2013.06.006_bib83","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1053\/gast.2000.19289","article-title":"The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group","volume":"119","author":"McHutchison","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2013.06.006_bib84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/SMJ.0b013e31825f033e","article-title":"Telaprevir and boceprevir in African Americans with genotype 1 chronic hepatitis C: implications for patients and providers","volume":"105","author":"Burton","year":"2012","journal-title":"South Med J"},{"key":"10.1016\/j.cgh.2013.06.006_bib85","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hep.24358","article-title":"Racial differences in hepatitis C treatment eligibility","volume":"54","author":"Melia","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib86","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib87","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib88","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-139-10-200311180-00009","article-title":"The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update","volume":"139","author":"El-Serag","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib89","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1542-3565(04)00353-2","article-title":"Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis","volume":"2","author":"Nguyen","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2013.06.006_bib90","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10620-007-9872-7","article-title":"Ethnic differences in hepatocellular carcinoma: implications for liver transplantation","volume":"53","author":"Kemmer","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2013.06.006_bib91","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/lt.21744","article-title":"Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus","volume":"15","author":"Thuluvath","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2013.06.006_bib92","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(02)07494-9","article-title":"Effect of race on outcome of orthotopic liver transplantation: a cohort study","volume":"359","author":"Nair","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2013.06.006_bib93","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.510280333","article-title":"Predictors of patient and graft survival following liver transplantation for hepatitis C","volume":"28","author":"Charlton","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2013.06.006_bib94","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib95","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","article-title":"Telaprevir and peginterferon with or without ribavirin for chronic HCV infection","volume":"360","author":"Hezode","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib96","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"McHutchison","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib97","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2013.06.006_bib98","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2013.06.006_bib99","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356513008653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356513008653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:15:17Z","timestamp":1761542117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356513008653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1542356513008653"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2013.06.006","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B and C in African Americans: Current Status and\u00a0Continued\u00a0Challenges","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2013.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}